ClinicalTrials.gg
TerminatedNCT02261883Updated Mar 5, 2024Results posted

Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

A Phase 2 interventional study of IV Remodulin and Placebo in Persistent Pulmonary Hypertension of the Newborn, sponsored by United Therapeutics. Terminated at 14 sites in United States. Open to participants aged 1 Hour to 14 Days. Per ClinicalTrials.gov, last updated 2024-03-05.

Sponsored by United Therapeutics · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
1 Hour to 14 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Persistent Fetal Circulation Syndrome with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Persistent Fetal Circulation Syndrome · United States.

Enrollment
6th of 12
42 · median 38
Started
2015
the only one that year
Phase 2
3 of 16
none open now
Registered
14th of 16
by date
Lead sponsor
1 of 16
United Therapeutics

Among the 16 studies in Persistent Fetal Circulation Syndrome with a site in United States, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2015, is one of 3 in phase 2, and was the 14th registered.

Persistent Fetal Circulation Syndrome

40 studies on the registry are indexed under Persistent Fetal Circulation Syndrome; 6 are open to participants now.

Browse Persistent Fetal Circulation Syndrome studies →

Open to participants now

1 of the 16 studies in Persistent Fetal Circulation Syndrome with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Persistent Fetal Circulation Syndrome studies recruiting now, 2 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 1 Hour to 14 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Persistent Fetal Circulation Syndrome with a site in United States, or all of them as a file.
02

Study summary

This study assessed the safety and treatment effect of intravenous (IV) Remodulin as an add-on therapy in neonates with persistent pulmonary hypertension of the newborn (PPHN).

Read the detailed description

This study was designed to investigate if the addition of Remodulin reduced the rate of clinical worsening (defined as the need for additional treatment targeting PPHN, need for extracorporeal mechanical oxygenation [ECMO], or death) in neonatal subjects with PPHN who did not show an adequate response to inhaled nitric oxide (iNO). This study was part of a pediatric investigation plan agreed upon by the EMA (EMEA 000207-PIP01-08-M08).

03

Conditions studied

  • Persistent Pulmonary Hypertension of the Newborn

Keywords

  • PPHN
04

Who can participate

Ages eligible
1 Hour to 14 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parent(s) or legal guardian provided consent for the subject to participate
  • Weight at least 2 kg at Screening
  • Gestational age of ≥34 weeks and ≤14 days old at Screening
  • Diagnosis of PPHN, which was either idiopathic in nature or associated with the following: meconium aspiration syndrome, pneumonia, respiratory distress syndrome, sepsis, birth hypoxia, perinatal encephalopathy, or unilateral congenital diaphragmatic hernia
  • Currently requiring ventilator support
  • Two consecutive oxygenation index (OI) of 15 or greater separated by at least 30 minutes, after receiving iNO for at least 3 hours
  • Echocardiographic (ECHO) evidence of pulmonary hypertension with elevated right ventricle pressure
  • Dedicated venous access for the administration of study drug (central line or peripherally inserted central venous catheter)

Exclusion criteria

Exclusion Criteria:

  • Previous or concurrent use of a phosphodiesterase-5 inhibitor, endothelin receptor antagonist, or prostanoid
  • Significant congenital heart disease as detected by ECHO, minor valvular abnormalities, or expected transitional findings such as a patent foramen ovale, or patent ductus arteriosus.
  • , untreated active pneumothorax at Screening
  • Evidence of clinically significant bleeding at Screening
  • Necrotizing enterocolitis (≥Bells stage II at Screening)
  • Uncontrolled hypotension (mean systemic pressures ≤35 mmHg at Screening)
  • Uncontrolled coagulopathy and / or untreated thrombocytopenia (\<50,000 /µL at Screening)
  • History of severe (Grade 3 or 4) intracranial hemorrhage at Screening
  • Currently receiving extracorporeal mechanical oxygenation (ECMO) or had immediate plans to initiate ECMO
  • Expected duration on mechanical ventilation of \<48 hours
  • was less than 2 months or had a lethal chromosomal anomaly
  • to ECMO
  • Bilateral congenital diaphragmatic hernia
  • Active seizures at Screening
  • Currently participating in another clinical drug study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Active comparator
    IV Remodulin

    The starting dose was 1 ng/kg/min (not to exceed to 2 ng/kg/min) and was titrated by up to 2 ng/kg/min every 2 hours, as tolerated and clinically indicated by the Investigator. Doses were titrated and maximized throughout the study until the desired clinical effect was observed or to each individual subject's maximally tolerated dose. There was no maximum dose.

    Drug: IV Remodulin

  • Placebo comparator
    Placebo

    The starting dose was 1 ng/kg/min (not to exceed to 2 ng/kg/min) and was titrated by up to 2 ng/kg/min every 2 hours, as tolerated and clinically indicated by the Investigator. Doses were titrated and maximized throughout the study until the desired clinical effect was observed or to each individual subject's maximally tolerated dose. There was no maximum dose.

    Drug: Placebo

Interventions

  • Treprostinil is a chemically stable tricyclic analogue of prostacyclin.

    Also known as: Treprostinil

  • DrugPlacebo

    Sodium citrate, sodium chloride, sodium hydroxide pellets, metacresol, and citric acid (anhydrous).

06

What researchers measure

Primary outcomes

  1. Number of Subjects Experiencing Clinical Worsening

    Clinical worsening was a composite endpoint defined by the occurrence of 1 of the following: death, initiation of ECMO per institutional policies, or need for additional treatment (initiation of additional targeted pulmonary vasodilator therapy).

    Time frame: From Baseline to Day 14

Secondary outcomes

  1. Change in Oxygenation Index (OI)

    OI is an assessment of how much oxygen from the lungs enters the blood when a subject inhales, calculated as: mean airway pressure (MAP) multiplied by fraction of inspired oxygen (FiO2) divided by partial pressure of oxygen in the arterial blood (PaO2), then multiplying by 100. An OI of 15 or less indicates mild hypoxia, 16 to 25 indicates moderate hypoxia, 26 to 40 indicates severe hypoxia, and more than 40 indicates very severe hypoxia.

    Time frame: From Baseline to Hours 12, 24, and 72; Days 7 and 14; and/or prior to study drug discontinuation/weaning

  2. Change in P/F Ratio

    PaO2/FiO2 ratio, also referred to as P/F Ratio, is a calculation used to assess the severity of hypoxemia, which is a condition characterized by low levels of oxygen in the blood. A low P/F ratio suggests that the patient's oxygen levels are compromised relative to the amount of oxygen being provided.

    Time frame: From Baseline to Hours 12, 24, and 72

  3. Change in Pre- and Post-ductal Oxygen Saturation (SpO2)

    SpO2 is an assessment of how much oxygen is in the blood, measured by a pulse oximeter. Pre-ductal SpO2 is measured in the right hand or foot and is a reflection of the amount of oxygen flowing to the brain. Post-ductal SpO2 is measured in the left hand or foot, after the blood has mixed with less oxygenated blood from the rest of the body.

    Time frame: From Baseline to Hours 6, 12, 24, and 72

  4. Change in N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP)

    NT-proBNP is a hormone produced by the heart. Increased NT-proBNP concentration is associated with changes in right heart morphology and function. The main purpose of NT-proBNP testing is to see if the blood levels of this protein are within the expected range for a healthy individual.

    Time frame: From Baseline to Days 1, 2, 3, 7, and 14 (or prior to hospital discharge)

  5. Time to Clinical Worsening

    Clinical worsening was assessed continuously during the study. Clinical worsening was a composite endpoint defined by the occurrence of 1 of the following: death, initiation of ECMO per institutional policies, or need for additional treatment (initiation of additional targeted pulmonary vasodilator therapy).

    Time frame: From Baseline to Day 56

  6. Time to Initiation of ECMO

    Start of ECMO was assessed continuously during the study. ECMO is a life-support therapy that oxygenates blood by passing it through an artificial lung. The start time of ECMO, if needed, was recorded for each subject.

    Time frame: From Baseline to Day 56

  7. Time to Discontinuation of Inhaled Nitric Oxide (iNO)

    Discontinuation of iNO was assessed continuously during the study. iNO works by relaxing the blood vessels in the lungs, which makes it easier for oxygen to be delivered to the body. The stop time of iNO was recorded for each subject.

    Time frame: From Baseline to Day 56

07

Results

Posted Mar 5, 2024

Participant flow

Participant flow — Overall Study
MilestoneIV RemodulinPlacebo
Started2121
Completed1518
Not completed63
Withdrew: Death32
Withdrew: Physician decision10
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject01
Withdrew: Required ecmo prior to study drug administration10

Outcome measures

PrimaryNumber of Subjects Experiencing Clinical Worsening

Clinical worsening was a composite endpoint defined by the occurrence of 1 of the following: death, initiation of ECMO per institutional policies, or need for additional treatment (initiation of additional targeted pulmonary vasodilator therapy).

Time frame:
From Baseline to Day 14
Reported as:
Count of participants · Participants
Number of Subjects Experiencing Clinical Worsening
ParticipantsIV RemodulinPlacebo
Yes812
No129
SecondaryChange in Oxygenation Index (OI)

OI is an assessment of how much oxygen from the lungs enters the blood when a subject inhales, calculated as: mean airway pressure (MAP) multiplied by fraction of inspired oxygen (FiO2) divided by partial pressure of oxygen in the arterial blood (PaO2), then multiplying by 100. An OI of 15 or less indicates mild hypoxia, 16 to 25 indicates moderate hypoxia, 26 to 40 indicates severe hypoxia, and more than 40 indicates very severe hypoxia.

Time frame:
From Baseline to Hours 12, 24, and 72; Days 7 and 14; and/or prior to study drug discontinuation/weaning
Reported as:
Median · units on a scale
Change in Oxygenation Index (OI)
units on a scaleIV RemodulinPlacebo
12 Hours-2.0 (-41 to 37)-3.5 (-29 to 34)
24 Hours-8.5 (-40 to 23)-5.5 (-30 to 58)
72 Hours-7.0 (-40 to 65)-10.0 (-41 to 83)
Day 7-9.5 (-40 to 36)-11.0 (-43 to 42)
Day 14-12.0 (-40 to 36)-14.0 (-35 to 42)
SecondaryChange in P/F Ratio

PaO2/FiO2 ratio, also referred to as P/F Ratio, is a calculation used to assess the severity of hypoxemia, which is a condition characterized by low levels of oxygen in the blood. A low P/F ratio suggests that the patient's oxygen levels are compromised relative to the amount of oxygen being provided.

Time frame:
From Baseline to Hours 12, 24, and 72
Reported as:
Median · ratio
Change in P/F Ratio
ratioIV RemodulinPlacebo
12 Hours0.11 (-0.5 to 10.5)0.10 (-2.3 to 4.1)
24 Hours0.35 (-0.4 to 9.3)0.27 (-2.3 to 7.1)
72 Hours0.50 (-0.4 to 4.8)0.65 (-2.3 to 7.5)
SecondaryChange in Pre- and Post-ductal Oxygen Saturation (SpO2)

SpO2 is an assessment of how much oxygen is in the blood, measured by a pulse oximeter. Pre-ductal SpO2 is measured in the right hand or foot and is a reflection of the amount of oxygen flowing to the brain. Post-ductal SpO2 is measured in the left hand or foot, after the blood has mixed with less oxygenated blood from the rest of the body.

Time frame:
From Baseline to Hours 6, 12, 24, and 72
Reported as:
Median · percentage of oxygen
Change in Pre- and Post-ductal Oxygen Saturation (SpO2)
percentage of oxygenIV RemodulinPlacebo
6 Hours3.0 (-6 to 13)1.0 (-10 to 7)
12 Hours3.0 (-7 to 17)0.5 (-7 to 12)
24 Hours3.0 (-12 to 15)1.0 (-17 to 11)
72 Hours0.0 (-4 to 16)1.5 (-21 to 8)
SecondaryChange in N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP)

NT-proBNP is a hormone produced by the heart. Increased NT-proBNP concentration is associated with changes in right heart morphology and function. The main purpose of NT-proBNP testing is to see if the blood levels of this protein are within the expected range for a healthy individual.

Time frame:
From Baseline to Days 1, 2, 3, 7, and 14 (or prior to hospital discharge)
Reported as:
Median · pg/mL
Change in N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP)
pg/mLIV RemodulinPlacebo
Day 1-1577.00 (-21322.0 to 43388.0)-1378.00 (-23206.0 to 17923.0)
Day 2-1955.00 (-24637.0 to 34599.0)-4090.00 (-37390.0 to 14163.0)
Day 3-252.00 (-24623.0 to 30629.0)-4090.00 (-49200.0 to 13550.0)
Day 7484.00 (-24623.0 to 19970.0)-11312.00 (-65387.0 to 12299.0)
Day 14-719.00 (-26283.0 to 56529.0)-9003.00 (-65387.0 to 12299.0)
SecondaryTime to Clinical Worsening

Clinical worsening was assessed continuously during the study. Clinical worsening was a composite endpoint defined by the occurrence of 1 of the following: death, initiation of ECMO per institutional policies, or need for additional treatment (initiation of additional targeted pulmonary vasodilator therapy).

Time frame:
From Baseline to Day 56
Reported as:
Median · days
Time to Clinical Worsening
daysIV RemodulinPlacebo
Time to Clinical Worsening3.0 (1 to 8)3.0 (1 to 13)
SecondaryTime to Initiation of ECMO

Start of ECMO was assessed continuously during the study. ECMO is a life-support therapy that oxygenates blood by passing it through an artificial lung. The start time of ECMO, if needed, was recorded for each subject.

Time frame:
From Baseline to Day 56
Reported as:
Median · days
Time to Initiation of ECMO
daysIV RemodulinPlacebo
Time to Initiation of ECMO2.5 (1 to 8)3.0 (1 to 5)
SecondaryTime to Discontinuation of Inhaled Nitric Oxide (iNO)

Discontinuation of iNO was assessed continuously during the study. iNO works by relaxing the blood vessels in the lungs, which makes it easier for oxygen to be delivered to the body. The stop time of iNO was recorded for each subject.

Time frame:
From Baseline to Day 56
Reported as:
Median · days
Time to Discontinuation of Inhaled Nitric Oxide (iNO)
daysIV RemodulinPlacebo
Time to Discontinuation of Inhaled Nitric Oxide (iNO)7.5 (1 to 12)7.0 (1 to 11)

Adverse events

Collected over Adverse events (AEs) were captured from when the subject signed the informed consent form until the subject completed the study or was withdrawn from the study, up to 56 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IV Remodulin4/20 (20%)8/20 (40%)19/20 (95%)
Placebo2/21 (9.5%)3/21 (14.3%)17/21 (81%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventIV RemodulinPlacebo
Cardio-respiratory arrestCardiac disorders1/200/21
Congenital diaphragmatic herniaCongenital, familial and genetic disorders1/200/21
HypotensionVascular disorders1/200/21
HypoxiaRespiratory, thoracic and mediastinal disorders1/201/21
Laryngeal stenosisRespiratory, thoracic and mediastinal disorders1/200/21
PneumothoraxRespiratory, thoracic and mediastinal disorders1/200/21
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders1/201/21
Pyloric stenosisCongenital, familial and genetic disorders1/200/21
Renal impairmentRenal and urinary disorders1/200/21
SepsisInfections and infestations1/200/21
Most frequent other events
Showing 10 of 14
Most frequent other events
EventIV RemodulinPlacebo
HypotensionVascular disorders6/203/21
AnaemiaBlood and lymphatic system disorders5/204/21
ThrombocytopeniaBlood and lymphatic system disorders4/201/21
Drug withdrawal syndrome neonatalGeneral disorders3/200/21
Alanine aminotransferase increasedInvestigations3/200/21
Aspartate aminotransferase increasedInvestigations3/200/21
Dermatitis diaperSkin and subcutaneous tissue disorders3/201/21
ConstipationGastrointestinal disorders2/200/21
SeizureNervous system disorders2/201/21
HypoxiaRespiratory, thoracic and mediastinal disorders2/201/21

Baseline characteristics

Intent-to-Treat Population

Age, Continuous
Age, Continuous(days)IV RemodulinPlaceboTotal
Median2.0 (1 to 6)3.0 (1 to 6)3.0 (1 to 6)
Sex: Female, Male
Sex: Female, Male(Participants)IV RemodulinPlaceboTotal
Female101020
Male101121
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IV RemodulinPlaceboTotal
Hispanic or Latino325
Not Hispanic or Latino171936
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IV RemodulinPlaceboTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American51015
White121123
More than one race101
Unknown or Not Reported101
Gestational Age
Gestational Age(weeks)IV RemodulinPlaceboTotal
Median39.00 (34.0 to 41.0)39.00 (34.0 to 41.2)39.00 (34.0 to 41.2)
Birth Weight
Birth Weight(kg)IV RemodulinPlaceboTotal
Median3.08 (2.2 to 4.8)3.06 (2.2 to 4.5)3.06 (2.2 to 4.8)
Oxygenation Index
Oxygenation Index(units on a scale)IV RemodulinPlaceboTotal
Median25.5 (4 to 46)22.0 (6 to 46)23.0 (4 to 46)
Fraction of Inspired Oxygen (FiO2)
Fraction of Inspired Oxygen (FiO2)(percentage of oxygen)IV RemodulinPlaceboTotal
Median100.0 (75 to 100)100.0 (35 to 100)100.0 (35 to 100)

6 further baseline measures are reported on the registry.

08

Study locations

14 sites
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Children's Hospital of Los Angeles
    Los Angeles, California 90027, United States
  • Stanford Children's Hospital
    Palo Alto, California 94304, United States
  • All Children's Hospital
    Saint Petersburg, Florida 33701, United States
  • Ann and Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • University of Mississippi Medical Center - Baston Children's Hospital
    Jackson, Mississippi 39216, United States
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Columbia University Medical Center
    New York, New York 10032-3784, United States
  • Nationwide Childrens Hospital
    Columbus, Ohio 43205, United States
  • Cook Children's Medical Center
    Fort Worth, Texas 76104, United States
  • University of Virginia Health Systems (UVA)
    Charlottesville, Virginia 22908, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Children's Hospital of Wisconsin
    Wauwatosa, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2015 to primary completion in Sep 2022, 85 months.

Results were first posted in Mar 2024, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2013
First posted
Oct 10, 2014
StartActual
Jul 29, 2015
Primary completionActual
Sep 27, 2022
CompletionActual
May 17, 2023
Results first posted
Mar 5, 2024
Last update
Mar 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02261883
Responsible party
Sponsor
First posted
Oct 10, 2014
Start date
Jul 29, 2015
Primary completion
Sep 27, 2022
Completion
May 17, 2023
Results posted
Mar 5, 2024
Last update
Mar 5, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion